Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura

Internal Medicine Journal

Volumn 41, Issue 2, 2011, Pages 202-205

  Le Guenno, G ^a   Ruivard, M ^a   Charra, L ^a   Philippe, P ^a  

^a HÔTEL DIEU   (France)

Author keywords

Immune thrombocytopenic purpura; Rituximab; Serum sickness

Indexed keywords

DEXCHLORPHENIRAMINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN D ANTIBODY; METHYLPREDNISOLONE; PARACETAMOL; PREDNISOLONE; PREDNISONE; RHOPHYLAC; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNITY; BLEEDING; BLOOD TRANSFUSION; CASE REPORT; EPISTAXIS; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PRIORITY JOURNAL; PURPURA; SERUM SICKNESS; THROMBOCYTE COUNT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PURPURA, THROMBOCYTOPENIC; SERUM SICKNESS;

EID: 79952031699     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02384.x     Document Type: Article

References (24)

1. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S etal. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
2. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC etal. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 2639-42.
3. Catuogno M, Rezai S, Priori R, Magrini L, Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford) 2005; 44: 406.
4. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44: 1717-8.
5. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J etal. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
6. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S etal. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310-7.
7. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13: 94-5.
8. Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O etal. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 2009; 89: 305-9.
9. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14: 1792.
10. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002; 70: 329.
11. Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F etal. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol 2008; 81: 165-9.
12. Mehsen N, Yvon CM, Richez C, Schaeverbeke T. Serum sickness following a first rituximab infusion with no recurrence after the second one. Clin Exp Rheumatol 2008; 26: 967.
13. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K etal. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740-50.
14. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol 2006; 135: 147.
15. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M etal. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007; 66: 351-7.
16. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005; 146: 217-21.
17. DeMonaco NA, Jacobs SA. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med 2007; 32: 933-4.
18. Disperati P, Hicks LK, Buckstein R. Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma 2007; 48: 1633-5.
19. Matsui T, Hidaka M, Kawakita T, Inoue Y, Sakai T, Harada N etal. Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies. Rinsho Ketsueki 2009; 50: 304-8.
20. Portlock CS, O'Connor OA, Straus DJ, Rosenzweig L, Dumitrescu O, Lin O etal. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation? Leuk Lymphoma 2006; 47: 1260-4.
21. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90: 829-32.
22. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34: 430-3.
23. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ etal. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9.
24. van Zandbergen G, van Kooten C, Mohamad NK, Reterink TJ, de Fijter JW, van de Winkel JG etal. Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89. Nephrol Dial Transplant 1998; 13: 3058-64.